TOC
Home > People at the DRFZ > Prof. Dr. Gerhard Krönke

Prof. Dr. Gerhard Krönke

Programme Area 4, PA 4 – Translational Rheumatology

Group leader: Clinical Rheumatology

Liaison working group with Charité - Rheumatology and Clinical Immunology

+49 30 450 570 400

gerhard.kroenke@charite.de

Scientific Background

Since 2023rnAppointed  Professor (W3) of Internal Medicine and Director of the Department of Rheumatology and Clinical Immunology, Charité Berlinrnrn2016 – 2023rnAppointed Professor (W2) of Translational Immunology at the University of Erlangen – Nurembergrnrn2012 – 2023rnSenior Physician at the Department of Internal Medicine 3, Rheumatology and Clinical Immunology, University Hospital Erlangenrnrn2009 – 2015rnJunior Group Leader at the Nikolaus Fiebiger Center of Molecular Medicine, University of Erlangen-Nurembergrnrn2006 – 2018rnResident in Internal Medicine and Rheumatology at the Department of Internal Medicine Rheumatology and Clinical Immunology, University Hospital Erlangenrnrn2004 – 2006rnPostdoctoral Fellow at the Cardiovascular Research Centre, University of Virginia, USArnrn2002 – 2004rnPostdoctoral Fellow at the Institute of Vascular Biology and Thrombosis Research, Medical University of Vienna, Austria

2018rnBoard certificate in Rheumatology, Rheumatology and Immunology, University hospital Erlangenrnrn2015rnMHBA (Master of Health and Business Administration) from the University of Erlangen- Nurembergrnrn2014rnVenia Legendi (PD) in Internal Medicinernrn2012rnBoard certificate in Internal Medicinernrn2002rnDoctorate (Dr. med.), M.D. Thesis under supervision of Bernd R. Binder, Institute of Vascular Biology, Vienna, Austriarnrn1996 – 2002rnMedical School, Medical University of Vienna, Austria

Peer reviewing activity for international journals including Nature, Nature Medicine, Nature Immunology, Immunity, PNAS, The Journal of Clinical Investigation, Nature Reviews Immunology, Nature Communications, The Journal of Experimental Medicine, Annals of the Rheumatic Diseases, Arthritis and Rheumatology as well as for funding agencies including the German Research foundation (DFG), Agence Nationale de la Recherche (ANR), Swiss National Science Foundation (SNSF), Israel Science Foundation, Jubiläumsfonds der Oesterreichische Nationalbank and the Austrian Wissenschaftsfonds (FWF).

German Society of Immunology (DGfI), German Society of Rheumatology (DGRh), German Society of Internal Medicine (DGIM)

2018rnMosaic of Autoimmunity (MAI) Award at the 11th International Congress of Autoimmunity, Lisbon, Portugalrnrn2018rnTheodor Naegeli Award from the Theodor Naegeli foundation Baselrnrn2017rnLangener Wissenschaftspreis from the Paul Ehrlich Instituternrn2013rnGeorges Köhler Award from the German Society of Immunologyrnrn2005rnMax Kade Postdoctoral Fellowship from the National Academy of Sciences, Austriarnrn2003rnNew Investigator Award at the 4th Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology, Washington DC, USA.

TOP 5 PUBLICATIONS

Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids Auger JP, Zimmermann M, Faas M, Stifel U, Chambers D, Krishnacoumar B, Taudte RV, Grund C, Erdmann G, Scholtysek C, Uderhardt S, Ben Brahim O, Pascual Maté M, Stoll C, Böttcher M, Palumbo-Zerr K, Mangan MSJ, Dzamukova M, Kieler M, Hofmann M, Blüml S, Schabbauer G, Mougiakakos D, Sonnewald U, Hartmann F, Simon D, Kleyer A, Grüneboom A, Finotto S, Latz E, Hofmann J, Schett G, Tuckermann J, Krönke G. (2024) Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature. d10.1038/s41586024-07282-7.
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus Mackensen A*, Müller F*, Mougiakakos D*, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G*, Schett G*. (2022). Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 28(10):2124-2132. doi:10.1038/s41591-022-02017-5. *equally contributed
IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation Faas M, Ipseiz N, Ackermann J, Culemann S, Grüneboom A, Schröder F, Rothe T, Scholtysek C, Eberhardt M, Böttcher M, Kirchner P, Stoll C, Ekici AB, Fuchs M, Kunz M, Weigmann B, Wirtz S, Lang R, Hofmann J, Vera J, Voehringer D, Michelucci A, Mougiakakos D, Uderhardt S, Schett G, Krönke G. (2021). IL-33- induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation. Immunity. 54(11):2531-2546.e5. doi:10.1016/j.immuni.2021.09.010.
Locally renewing resident synovial macrophages provide a protective barrier for the joint Culemann S, Grüneboom A, Nicolás-Ávila JA, Weidner D, Lämmle K, Rothe T, Quintana J, Kirchner P, Krljanac B, Eberhardt M, Ferrazzi F, Kretzschmar E, Schicht M, Fischer K, Gelse K, Faas M, Pfeifle R, Ackermann JA, Pachowsky M, Renner N, Simon D, Haseloff RF, Ekici AB, Bäuerle T, Blasig I, Vera J, Voehringer D, Kleyer A, Paulsen F, Schett G, Hidalgo A, Krönke G. (2019). Locally renewing resident synovial macrophage provide a protective barrier for the joint. Nature. 572(7771):670-675. doi: 10.1038/s41586-019-1471-1.
Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease Pfeifle R, Rothe T, Ipseiz N, Scherer HU, Culemann S, Harre U, Ackermann JA, Seefried M, Kleyer A, Uderhardt S, Haugg B, Hueber AJ, Daum P, Heidkamp GF, Ge C, Böhm S, Lux A, Schuh W, Magorivska I, Nandakumar KS, Lönnblom E, Becker C, Dudziak D, Wuhrer M, Rombouts Y, Koeleman CA, Toes R, Winkler TH, Holmdahl R, Herrmann M, Blüml S, Nimmerjahn F, Schett G, Krönke G. (2017). Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease. Nat Immunol. (1):104-113. doi: 10.1038/ni.3579.

Krönke lab

Investigating the molecular basis of inflammation and development of curative treatment approaches
learn more

news

Go to end of slider
  • Publications

New mechanism of cortisone action deciphered

Cortisone has been used for decades to treat chronic inflammation, for example is patients with rheumatic diseases; however, the underlying molecular mechanism of action was…